242 related articles for article (PubMed ID: 24807840)
1. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies.
Zhu J; Lin Z; Wu J; Yin H; Dai J; Feng Z; Marrero J; Lubman DM
J Proteome Res; 2014 Jun; 13(6):2986-97. PubMed ID: 24807840
[TBL] [Abstract][Full Text] [Related]
2. Mass Spectrometric N-Glycan Analysis of Haptoglobin from Patient Serum Samples Using a 96-Well Plate Format.
Zhu J; Wu J; Yin H; Marrero J; Lubman DM
J Proteome Res; 2015 Nov; 14(11):4932-9. PubMed ID: 26448449
[TBL] [Abstract][Full Text] [Related]
3. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
Peta V; Zhu J; Lubman DM; Huguet S; Imbert-Bismutd F; Bolbach G; Clodic G; Matheron L; Ngo Y; Raluca P; Housset C; Rezai K; Poynard T;
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):681-691. PubMed ID: 31964615
[TBL] [Abstract][Full Text] [Related]
4. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma.
Yin H; Lin Z; Nie S; Wu J; Tan Z; Zhu J; Dai J; Feng Z; Marrero J; Lubman DM
J Proteome Res; 2014 Jun; 13(6):2887-96. PubMed ID: 24799124
[TBL] [Abstract][Full Text] [Related]
5. Mass-Selected Site-Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma.
Yin H; Tan Z; Wu J; Zhu J; Shedden KA; Marrero J; Lubman DM
J Proteome Res; 2015 Nov; 14(11):4876-84. PubMed ID: 26403951
[TBL] [Abstract][Full Text] [Related]
6. ESI-LC-MS Method for Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis.
Zhang Y; Zhu J; Yin H; Marrero J; Zhang XX; Lubman DM
J Proteome Res; 2015 Dec; 14(12):5388-95. PubMed ID: 26503433
[TBL] [Abstract][Full Text] [Related]
7. Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.
Pompach P; Brnakova Z; Sanda M; Wu J; Edwards N; Goldman R
Mol Cell Proteomics; 2013 May; 12(5):1281-93. PubMed ID: 23389049
[TBL] [Abstract][Full Text] [Related]
8. Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease.
Sanda M; Pompach P; Brnakova Z; Wu J; Makambi K; Goldman R
Mol Cell Proteomics; 2013 May; 12(5):1294-305. PubMed ID: 23389048
[TBL] [Abstract][Full Text] [Related]
9. Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection.
Dalal K; Dalal B; Bhatia S; Shukla A; Shankarkumar A
Clin Chim Acta; 2019 Aug; 495():309-317. PubMed ID: 31014754
[TBL] [Abstract][Full Text] [Related]
10. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
11. N-linked glycan changes of serum haptoglobin β chain in liver disease patients.
Zhang S; Shu H; Luo K; Kang X; Zhang Y; Lu H; Liu Y
Mol Biosyst; 2011 May; 7(5):1621-8. PubMed ID: 21380457
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer.
Lin Z; Simeone DM; Anderson MA; Brand RE; Xie X; Shedden KA; Ruffin MT; Lubman DM
J Proteome Res; 2011 May; 10(5):2602-11. PubMed ID: 21417406
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies.
Liang J; Zhu J; Wang M; Singal AG; Odewole M; Kagan S; Renteria V; Liu S; Parikh ND; Lubman DM
Sci Rep; 2019 Aug; 9(1):11580. PubMed ID: 31399619
[TBL] [Abstract][Full Text] [Related]
14. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.
Huang Y; Zhou S; Zhu J; Lubman DM; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2160-2167. PubMed ID: 28543513
[TBL] [Abstract][Full Text] [Related]
15. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development.
Asazawa H; Kamada Y; Takeda Y; Takamatsu S; Shinzaki S; Kim Y; Nezu R; Kuzushita N; Mita E; Kato M; Miyoshi E
Clin Chem Lab Med; 2015 Jan; 53(1):95-102. PubMed ID: 25060348
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.
Ferrín G; Rodríguez-Perálvarez M; Aguilar-Melero P; Ranchal I; Llamoza C; Linares CI; González-Rubio S; Muntané J; Briceño J; López-Cillero P; Montero-Álvarez JL; de la Mata M
PLoS One; 2015; 10(3):e0118527. PubMed ID: 25789864
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma and its early detection by AFP testing in Mongolia.
Oyunsuren T; Sanduijav R; Davaadorj D; Nansalmaa D
Asian Pac J Cancer Prev; 2006; 7(3):460-2. PubMed ID: 17059345
[TBL] [Abstract][Full Text] [Related]
18. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients.
Zekri AR; Youssef AS; Bakr YM; Gabr RM; El-Rouby MN; Hammad I; Ahmed EA; Marzouk HA; Nabil MM; Hamed HA; Aly YH; Zachariah KS; Esmat G
Asian Pac J Cancer Prev; 2015; 16(3):1281-7. PubMed ID: 25735368
[TBL] [Abstract][Full Text] [Related]
19. A Potential Serum
Higashi M; Yoshimura T; Usui N; Kano Y; Deguchi A; Tanabe K; Uchimura Y; Kuriyama S; Suzuki Y; Masaki T; Ikenaka K
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255418
[TBL] [Abstract][Full Text] [Related]
20. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus.
Cong M; Ou X; Huang J; Long J; Li T; Liu X; Wang Y; Wu X; Zhou J; Sun Y; Shang Q; Chen G; Ma H; Xie W; Piao H; Yang Y; Gao Z; Xu X; Tan Z; Chen C; Zeng N; Wu S; Kong Y; Liu T; Wang P; You H; Jia J; Zhuang H
OMICS; 2020 Jul; 24(7):415-423. PubMed ID: 32522092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
